Virtual Therapy Habit Reversal Training for Body-Focused Repetitive Behaviors: Clinical Outcomes from a Large Real-World Sample of Youth and Adults

Jamie D. Feusner, M.D.[1-4]*, Clare C. Beatty, M.A.[1,5]*, Christopher Murphy, B.S., Patrick B. McGrath, Ph.D.[1], Nicholas R. Farrell, Ph.D.[1], Mia Nuñez, Ph.D.[1], Nicholas Lume, B.S.[1] Reza Mohideen, B.S.[1], Larry Trusky, B.S.[1], Stephen M. Smith, B.A.[1], Andreas Rhode, Ph.D.[1]

*These authors contributed equally to this work

[1]NOCD, Inc., Chicago, IL, 60601, US
[2]Department of Psychiatry, University of Toronto, Toronto, ON, Canada
[3]Centre for Addiction and Mental Health, Toronto, ON, Canada
[4]Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden

Funding/Support: No external funding was received for this analysis.

Relevant Financial Relationships: JDF, CCB, PBM, NRF, MN, LT, SMS, AR, NL, and RM report personal fees from NOCD Inc. CM has no relevant financial relationships to disclose.

Acknowledgments: The authors thank the NOCD therapists and Member Advocates for their help in facilitating treatment and care experiences.

Corresponding Author: Jamie D. Feusner, MD, NOCD, Inc., 225 Michigan Ave Ste 1430, Chicago, IL 60601, email: jamie@nocdhelp.com

ORCID: https://orcid.org/0000-0002-0391-345X

Abstract

Objective: To examine the effectiveness of virtual therapy-delivered habit reversal training (HRT) in large real-world samples of children, adolescents, and adults with trichotillomania and excoriation disorder.

Methods: The sample included 543 patients with trichotillomania (57 children, 75 adolescents, 408 adults) and 528 patients with excoriation disorder (40 children, 46 adolescents, 442 adults). Treatment followed a protocol of twice-weekly HRT sessions, transitioning to weekly sessions. The Repetitive Body Focused Behavior Scale (RBFBS) was administered at baseline, weeks 5-7, weeks 14-16, and during maintenance periods through week 52.

Results: At weeks 14-16, trichotillomania showed a median 33.33% severity reduction (IQR=11.11%-54.55%; 44.08% achieving ≥35% reduction) with large effects (Hedges' g=1.01, 95% CI [0.88, 1.14]). Excoriation showed a median 33.33% reduction (IQR=12.50%-57.14%; 48.66% achieving 35% reduction; g=1.16 [1.02-1.30]). Improvements were maintained through week 52 (trichotillomania: g=1.51 [CI: 1.23 to 1.79]; excoriation: g=1.56 [1.29-1.84]). Both conditions showed improvements in depression, anxiety, and stress (g=0.22-0.29). Mean treatment duration was 14.64±2.50 weeks (7.71±2.61 sessions) for trichotillomania and 14.54±2.69 weeks (7.73±2.68 sessions) for excoriation. All age groups improved, with effect sizes ranging from g=0.78-1.11 for trichotillomania and g=0.68-1.54 for excoriation.

Conclusion: This analysis demonstrates that virtual therapy-delivered HRT can effectively reduce both hair-pulling and skin-picking severity and improve related symptoms in a real-world setting. The large treatment effects and improvements across the lifespan for both conditions suggest this delivery format may help address barriers to accessing evidence-based care for body-focused repetitive behaviors.

Keywords:

Telehealth, teletherapy, digital behavioral health, HRT, trichotillomania, hair-pulling, excoriation disorder, skin-picking

Body-focused repetitive behaviors (BFRBs) are psychiatric conditions characterized by repetitive, ritualized behaviors directed at one's body, involving compulsively damaging one's physical appearance or causing physical injury [1]. While occasional engagement in these behaviors appears common in the general population, pathological forms causing significant distress and functional impairment affect approximately 12% of individuals [2]. These conditions are associated with elevated rates of anxiety and diminished quality of life [3]. The two most extensively studied BFRBs, now recognized as distinct disorders within the DSM-5's Obsessive-Compulsive and Related Disorders category, are trichotillomania and excoriation disorder[4].

Trichotillomania is characterized by recurrent hair pulling, leading to noticeable hair loss and functional impairment [4]. The first large-scale U.S. epidemiological survey found a point prevalence of 1.7% among adults [5,6], aligning with lifetime prevalence estimates of ~1-3% [7–12]. Trichotillomania typically onsets during early adolescence, between ages 10-12 [5,6,13,14] and frequently co-occurs with anxiety and depression [10,15]. Despite its impact on quality of life, approximately 65% of affected individuals never seek treatment [16].

Excoriation disorder (ED) is characterized by recurrent skin picking, leading to tissue damage and functional impairment (American Psychiatric Association, 2013). Prevalence estimates range from 1.4% to 5.4% in the general population [17,18], with a recent large-scale study finding that 2.1% of adults meet diagnostic criteria for the condition [6,19]. Excoriation disorder typically onsets during adolescence [20] and frequently co-occurs with depression, anxiety, and obsessive-compulsive disorder, which may contribute to increased symptom severity [21,22]. The condition often leads to significant physical scarring [19] and psychosocial impairment, including missed work and social obligations [23,24], yet like trichotillomania, many affected individuals do not seek mental health treatment.

For those who do seek treatment, Habit Reversal Training (HRT), a form of cognitive-behavioral therapy, is an effective form of treatment for BFRBs [25–27]. HRT helps patients develop awareness of picking and pulling behaviors and replace them with competing responses [28–30], incorporating self-monitoring, awareness training, competing response training, and stimulus control procedures.

HRT controlled studies have shown large effects (ES =-1.14), and superiority to pharmacological interventions [26] and controls [31,32]. Research also supports the effectiveness of HRT when enhanced with components from acceptance and commitment therapy (ACT)[33] and dialectical behavior therapy (DBT) components[34]. Evidence supports HRT's efficacy in youth with trichotillomania, with studies showing significant symptom reduction compared to control conditions[35] and superior outcomes (76% vs 21%, d =1.31; response rate) compared to treatment as usual, where youth continued their existing treatments including psychotherapy and medications [36]. Evidence also supports HRT's efficacy for excoriation disorder, with randomized controlled trials demonstrating symptom reduction [37,38], though primarily in short-term outcomes. While HRT demonstrates efficacy in controlled trials and generally maintains gains for 3-6 months post-treatment, many individuals do not respond or experience relapse, with 50-67% of initial treatment responders relapsing during long-term follow-up [39].

Despite the established efficacy of HRT, multiple barriers impede access to treatment for both trichotillomania and excoriation disorder. Provider limitations represent a significant challenge - a survey of healthcare professionals found that while they possessed basic trichotillomania knowledge, many endorsed non-empirically supported treatments and lacked resources for patients [40,41]. This knowledge gap is reflected in practice, with only 3% of hair pullers perceiving their providers as trichotillomania experts [16] and more than a quarter rating their providers as "not at all knowledgeable" about the condition. Recent studies continue to demonstrate that providers working with trichotillomania patients often lack sufficient knowledge about both the condition and its treatment options [40] Similar challenges exist for excoriation disorder, where many affected individuals seek dermatologic rather than mental health care due to limited provider expertise [42]. Geographic and cost barriers further compound these challenges, particularly affecting individuals in areas without specialized mental health services.

The rise of telehealth platforms offers a promising solution to expand access to BFRB treatment while addressing many traditional barriers. Virtual care delivery has become increasingly integrated into mental health services, potentially allowing patients to connect with knowledgeable providers regardless

of geographic location. Emerging research on technology-based interventions for BFRBs has shown encouraging results, with studies demonstrating effectiveness of virtually-delivered treatments in both provider-led interventions [43,44] and automated approaches [45] for trichotillomania. Initial studies examining telehealth delivery of acceptance-enhanced behavior therapy (AEBT), which integrates traditional HRT with acceptance and commitment therapy (ACT), have shown significant reductions in hair-pulling severity, with large effects observed for both adults (ω^2=.473)[43] and adolescents (Hedges' g=1.55)[44], with high patient satisfaction reported. However, research suggests that telehealth delivery of HRT may result in differential outcomes compared to in-person treatment, with factors such as technology familiarity and limited field of view potentially impacting effectiveness [46]. This consideration may be particularly relevant for excoriation disorder, where visual assessment of skin-picking behaviors and resulting damage is crucial for treatment monitoring [46].

While these initial clinical trials of remote HRT delivery are promising, research has not yet examined outcomes in large-scale, real-world clinical settings. NOCD, a virtual behavioral health provider specializing in obsessive-compulsive and related disorders, delivers HRT through virtual therapy with HRT-trained therapists, supplemented by between-session messaging and an online community platform. This study aimed to determine clinical outcomes in a large naturalistic sample of individuals with trichotillomania or excoriation disorder who received HRT via NOCD's online specialty therapy platform, addressing a critical gap in understanding the real-world effectiveness of technology-enabled remote treatment delivery.

Method

Sample

This was a retrospective, observational longitudinal analysis of clinical data from individuals who received HRT treatment for trichotillomania or excoriation disorder through NOCD's online specialty therapy platform between May 2021 and February 2025. We applied several inclusion criteria to the data that were included for both conditions: (1) valid baseline RBFBS assessment, (2) baseline RBFBS score > 0, (3) completion of ≥2 assessments, (4) completion of at least one follow-up assessment (weeks 5-7 OR weeks 14-16), and (5) a minimum of five treatment sessions. The final analysis included 543 trichotillomania patients (51.2% of 1,060 initial patients) and 528 excoriation disorder patients (43.2% of 1,222 initial patients)), including children, adolescents, and adults with primary diagnoses of their respective conditions.

Initial Evaluation and Clinical Assessments

Initial evaluations were conducted by NOCD-trained therapists using the Diagnostic Interview for Anxiety, Mood, and Obsessive-Compulsive and Related Neuropsychiatric Disorders (DIAMOND; [4,47]). Patients who met DSM-5 criteria for trichotillomania or excoriation disorder were eligible for treatment. Those rated as having "extreme" symptom severity were typically referred to more intensive treatment options (see Supplementary Material).

Treatment Approach

The NOCD treatment model delivered HRT through a structured virtual therapy. The initial phase included twice-weekly 60-minute video sessions for 2-3 weeks for most, followed by 10-14 weeks of weekly 60-minute sessions. Some transitioned to 30-minute check-in sessions based on clinical progress, symptom reduction, and mastery of HRT principles. All sessions used HIPAA-compliant video conferencing. Patients also had access to in-app messaging with their therapist, a mobile app for tracking, and a moderated online community. Treatment involved core HRT components (awareness training, competing response training, generalization training, and social supports[48]) and occasionally incorporated stimulus control strategies and functional analysis of the BFRBs[49,50]. Treatment was delivered by

therapists who completed intensive training in OCD-related disorders and HRT (see Supplementary Material for detailed training procedures). The treatment duration and session frequency were adjusted based on individual needs.

Assessments

While patients completed assessments every three weeks throughout treatment, we analyzed outcomes at three primary intervals: baseline, weeks 5-7 (to capture early treatment response), and weeks 14-16 (representing the primary endpoint). Additional assessments collected during follow-up periods (weeks 17-52) were analyzed to evaluate long-term outcomes (see Supplementary Material for detailed assessment timeline and procedures).

The primary outcome measure was the Repetitive Body Focused Behavior Scale (RBFBS[51]) administered in both self-report (RBFBS-SR) and parent-report (RBFBS-P) formats. The RBFBS assesses three types of body-focused repetitive behaviors (skin picking, hair pulling, and nail-biting) using 12 items. Respondents rate three domains on a 0-4 scale: time spent, interference, and distress (emotional impact, urge resistance). Hair-pulling and skin-picking subscale scores range from 0-12 (mild: 1-3, moderate: 4-6, severe: 7-9, extreme: 10-12). The parent-report version shows excellent internal consistency for hair pulling (α=.95) and skin picking (α=.93) subscales [51], while adult data supports convergent validity with established measures (r=.74 with GBS-8)[52–54].

Secondary measures assessed depression, anxiety, and stress (Depression, Anxiety, and Stress Scale; DASS-21[55]), quality of life (Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form; Q-LES-Q-SF[56]), and disability and functioning (World Health Organization Disability Assessment Schedule 2.0; WHODAS 2.0[57]). See Supplementary Material for complete measure descriptions.

Data Analysis

Treatment engagement metrics (messaging, app opens, visits) were calculated through week 16, analyzing message frequency and app usage patterns. Primary and secondary outcomes were analyzed using linear mixed models with assessment timepoint as a fixed factor, patient as a random factor, and respective outcome scores (BFRB severity, depression, anxiety, stress, quality of life, and disability) as

dependent variables. Age effects were examined by testing interactions between age group and evaluation timepoints.

Treatment response categories (≥45% improvement, ≥35% improvement, ≥25%, 0-24%, or worsened [58]) were based on meta-analyses of trichotillomania clinical trials [59–61]. Effect sizes were calculated using Hedges' g with 95% confidence intervals. Treatment duration effects were examined by comparing outcomes between shorter (14-18 weeks) and longer (30-36 weeks) durations. Analyses were conducted using R Statistical Software (v4.1.3). Detailed information about missing data and satisfaction analyses is provided in Supplementary Material.

Ethical Considerations

The analyses in this study did not require research ethics board review as this does not meet the criteria for Human Subject Research as defined by federal regulations for human subject protections, 45 CFR 46.102(e); this is a secondary analysis of de-identified data from clinical records, obtained and analyzed retrospectively, and was not the result of a research intervention or interaction. Compliance with data protection laws was ensured through NOCD's privacy policy, which all patients agreed to, outlining data use and protection measures.

Results

Sample

The analysis included 1,071 eligible patients with either trichotillomania or excoriation disorder (see Table 1 for detailed demographics). Both conditions showed a predominance of adult patients, though the age distribution differed between groups. The trichotillomania sample was 75.6% adult (mean age =31.0 years, SD =8.96), with 13.9% adolescents (mean age =14.9 years, SD =1.41) and 10.6% children (mean age =10.2 years, SD =1.83). The excoriation disorder sample was 83.7% adult (mean age =30.7 years, SD =9.87), with 8.7% adolescents (mean age =15.6 years, SD =1.22) and 7.6% children (mean age =10.5 years, SD =1.62).

Missing Data

Assessment completion patterns were similar between conditions. For trichotillomania, 77.7% provided weeks 14-16 assessments. For excoriation disorder, 77.5% provided weeks 14-16 assessments. Among participants who did not provide week 14-16 assessments, the median treatment duration was 11 weeks [IQR: 9-12] for trichotillomania and 10 [IQR: 9-12] weeks for excoriation disorder. More information can be found in Table 3 and Supplementary Results.

Overall Treatment Effects

For trichotillomania ($F_{2,974.04}=95.79$, P<.001), RBFBS scores decreased from a mean of 7.84 (SD 2.29) to a mean of 6.19 (SD 2.68) at week 5-7 (-1.65 points, 18.32%; Hedges g=0.66, 95% CI [0.57, 0.75], n=543), and to a mean of 5.27 (SD 2.73) at week 14-16 (-2.56 points, 29.90%; Hedges g=1.01, 95% CI [0.88, 1.14], n=422). For excoriation disorder ($F_{2,955.75}=321.99$, P<.001), RBFBS scores decreased from a mean of 7.89 (SD 2.14) to a mean of 6.34 (SD 2.51) at week 5-7 (-1.55 points, 17.51%; Hedges g=0.66, 95% CI [0.57, 0.75], n=528), and to a mean of 5.13 (SD 2.57) at week 14-16 (-2.74 points, 32.79%; Hedges g=1.16, 95% CI [1.02, 1.30], n=409).

Age Group Differences. For trichotillomania, there was a significant main effect of time ($F_{(2, 974.04)}=95.79$, p< .001), a significant effect of age category ($F_{(2, 534.61)}=17.43$, p< .001), and a significant age by time interaction ($F_{(4, 974.37)}=2.66$, p=.032). For excoriation disorder, there was a

significant main effect of time (F(2, 955.75)=321.99, p< .001), age category (F(2, 531.26)=19.58, p< .001), and age by time interaction (F(4, 954.88)=3.45, p=.008). At baseline in the trichotillomania sample, adults showed higher scores than both adolescents (difference = 0.809, p=.028) and children (difference = 2.249, p<.001). Similarly at baseline in the excoriation sample, adults showed higher scores than both adolescents (difference =1.52, p< .001) and children (difference =1.94, p< .001). Treatment effects varied across age groups for both conditions (trichotillomania: adults g=1.11 [0.96, 1.27], adolescents g=0.81 [0.46, 1.15], children g=0.78 [0.47, 1.09]; excoriation: adults g=1.23 [1.07, 1.39], adolescents g=0.68 [0.33, 1.03], children g=1.54 [0.99, 2.09]; see Table 2 for means and sample sizes by timepoint). Overall, while all age groups showed meaningful improvement, both conditions showed age-related differences in baseline severity and treatment response, with adults generally showing higher baseline severity and strong treatment effects across both conditions.

Individual-Level Changes and Response Rates

For trichotillomania, median RBFBS hair score improvement was 33.33% (IQR: 11.11% to 54.55%) at week 14-16, with week 5-7 median improvement at 14.29% (IQR: 0.0% to 38.75%). Among those with week 14-16 data, 33.2% (140/422) had ≥45% reduction, 44.1% (186/422) had ≥35% reduction, 60.9% (257/422) had ≥25% reduction, 90.5% (382/422) had ≥0% reduction, and 9.5% (40/422) showed worsening of symptoms.

For excoriation disorder, median RBFBS score improvement was 33.33% (IQR: 12.50%-57.14%), with week 5-7 median improvement at 14.29% (IQR: 0.00%-37.50%). Among those with week 14-16 data, 37.2% (152/409) had ≥45% reduction, 48.7% (199/409) had ≥35% reduction, 63.3% (259/409) had ≥25% reduction, 90.5% (370/409) had ≥0% reduction, and 9.5% (39/409) showed worsening of symptoms.

Depression, Anxiety, and Stress, Quality of Life and Disability

Both trichotillomania and excoriation disorder groups showed significant improvements in psychological symptoms, with small to moderate effects for depression (g=0.26-0.29), anxiety (g=0.22-0.26), and stress (g=0.27-0.28). Similar improvements were observed in functional outcomes, including

quality of life (g=-0.26-0.25) and disability (g=0.25-0.30) (all Ps<.001; see Table 3 for means, Supplemental Figure 1-2 for changes over time, and Supplementary Results for detailed analyses).

Longitudinal follow-up

Treatment gains were maintained or improved during follow-up periods through week 52 (trichotillomania: $F(5,1812.16)=212.27$, P<.001; excoriation: ($F(5,1425.68)=238.34$, P<.001). For trichotillomania, mean symptom reduction from baseline was 38.8% at weeks 17-28 (n=365; Hedges g=1.18 [95% CI: 1.03-1.34]), 42.2% at weeks 29-40 (n=229; g=1.34 [95% CI: 1.14-1.55]), and 45.5% at weeks 41-52 (n=122; g=1.51 [95% CI: 1.23-1.79]). Similarly for excoriation, mean symptom reduction from baseline was 40.9% at weeks 17-28 (n=345; g=1.44 [95% CI: 1.27-1.61]), 42.9% at weeks 29-40 (n=205; g=1.59 [95% CI: 1.37-1.81]), and 44.1% at weeks 41-52 (n=134; g=1.56 [95% CI: 1.29-1.84]). See Figure 2 and Supplementary Results for detailed longitudinal analyses.

Discussion

This retrospective observational study demonstrates that HRT delivered via virtual therapy is effective for treating both trichotillomania and excoriation disorder in a large naturalistic sample. Treatment resulted in significant symptom reduction, with trichotillomania and excoriation decreasing by a mean of 29.9% and 32.8% respectively (g=1.01 and 1.16). Moreover, 44.1% of trichotillomania patients and 48.7% of excoriation disorder patients achieved ≥35% reduction in symptoms. Treatment also resulted in significant improvements in commonly co-occurring symptoms of depression, anxiety, and stress (g=0.22-0.29), and both groups demonstrated improvements in quality of life (g= -0.26-0.25) and disability (g=0.25-0.30). These secondary outcome improvements suggest that targeted BFRB treatment can lead to broader functional recovery. Importantly, these improvements were not only maintained but continued to strengthen during extended follow-up periods through week 52. While sample sizes decreased during follow-up, as expected in a naturalistic setting, both conditions showed sustained or enhanced treatment gains, suggesting potential long-term benefits of virtual therapy-delivered HRT. These findings from a large-scale, real-world setting provide promising evidence for virtual therapy-delivered HRT as a treatment option for these historically under-treated conditions. This is particularly

important given that BFRBs typically onset around age 11[14] and remain chronic if untreated, with only

50% of trichotillomania patients[16] and 87.1% of excoriation disorder patients ever accessing care[62]. Even

when psychiatric referrals for BFRBs are made, the majority of patients do not successfully engage in

treatment [63], highlighting the critical need for more accessible treatment options.

While outcomes were analyzed at standardized timepoints (weeks 5-7 and 14-16), treatment

duration was determined by individual clinical needs. The mean treatment duration was 14.64±2.50

weeks (7.71±2.61 sessions) for trichotillomania and 14.54±2.69 weeks (7.73±2.68 sessions) for

excoriation, which aligns with typical HRT protocols, which have shown significant symptom reduction

across treatment periods ranging from 8 weekly sessions to several months [33,36,64,65]. While treatment

duration was comparable to in-person HRT, the virtual therapy format eliminated geographical barriers. It

also decreases travel burden and may have been associated with lower out-of-pocket costs for individual

patients through high insurance utilization (>80% of patients). This enhanced accessibility to specialized

BFRB treatment particularly benefits patients in areas with limited access to HRT specialists.

Despite HRT's established efficacy[26,27,66], significant barriers limit treatment access, spurring the

development of technology-enabled delivery methods. Initial internet-delivered self-help programs for

trichotillomania [67] and excoriation disorder [68] showed initial promise, but demonstrated modest outcomes

in controlled trials [69]. More recent studies of video-based teletherapy show promising outcomes. A

randomized trial demonstrated significant reductions in hair-pulling severity in adults, with improvements

maintained at 12-week follow-up [43]. Similarly, a pilot study of video-delivered treatment for adolescents

with trichotillomania showed significant symptom reduction with high treatment completion rates[44]. This

evolution in delivery method is especially valuable as individuals with BFRBs report openness to

internet-delivered interventions,[70] potentially addressing barriers related to shame and access.[71]

Our findings align with emerging evidence for technology-enabled BFRB treatment. A recent

large-scale evaluation of internet-based therapist-assisted programs (N=1,423) found significant symptom

reduction for both trichotillomania and excoriation disorder (d=0.82 and d=0.99, respectively)[72]. While

their treatment model shared some features with our approach−including licensed therapist support and

integration of HRT with other evidence-based components—our video-based structured sessions achieved stronger effects (Hedges g=1.01 for trichotillomania and Hedges g=1.16 for excoriation disorder), using a different delivery format than their self-paced, chat-based approach. Several key features of our platform may explain these outcomes. Real-time video sessions let therapists and patients interact while practicing exposures and exercises in typical environments where symptoms often occur. In-app messaging demonstrated high engagement (99-100% of patients sent messages, 97-99% sent 10+ messages), while symptom tracking tools and a moderated online community provided supplementary support that may have helped reduce social isolation commonly experienced with BFRBs. This approach thus combined effective HRT delivery with robust between-session engagement tools to address clinical and support needs.

Treatment outcomes were consistent across age groups. While adults initially showed higher severity scores in both conditions, endpoint differences remained only between adults/adolescents and children. These findings demonstrate that virtual therapy HRT can be effectively adapted across developmental stages. This is particularly important since BFRB symptoms typically onset in childhood/early adolescence[14], yet treatment is often delayed for years. Early virtual therapy intervention across age groups could help prevent the progression to more severe or chronic symptoms that occur with delayed treatment.

Several limitations warrant discussion. The observational design (thus, without a control group or randomization) precludes causal inferences about treatment effects, although our findings align with previous controlled HRT trials. A constraint was using the RBFBS as our primary outcome measure instead of the Generic BFRB Scale-8 (GBS-8) [54] or the Massachusetts General Hospital Hairpulling Symptom Severity Scale (MGH-HS) [53]. While the RBFBS parent-report shows strong psychometric properties in youth samples and the adult version demonstrates promising convergent validity with the GBS-8, the adult self-report version lacks comprehensive psychometric validation (including discriminant validity and internal consistency), and limits our ability to make direct comparisons with previous studies.

Additional limitations include a lack of formal treatment fidelity assessment (despite standardized training and supervision) and missing data, which reflects typical real-world treatment engagement.

In conclusion, virtual therapy-delivered HRT demonstrated clinically significant improvements in both trichotillomania and excoriation disorder symptoms across severity levels and age groups, while also improving depression, anxiety, stress, and quality of life outcomes in this large naturalistic sample. High engagement and strong insurance utilization suggest this treatment approach offers a scalable, accessible option for evidence-based care that could reduce the substantial gap between symptom onset and treatment typically seen in these conditions.

Abbreviations:
ACT =Acceptance and Commitment Therapy
ADHD =Attention Deficit Hyperactivity Disorder
AEBT =Acceptance-Enhanced Behavior Therapy
BFRB =Body-Focused Repetitive Behavior
CI =Confidence Interval
DASS-21 =Depression, Anxiety, and Stress Scales
DBT =Dialectical Behavior Therapy
DIAMOND =Diagnostic Interview for Anxiety, Mood, and Obsessive-Compulsive and Related Neuropsychiatric Disorders
ED =Excoriation Disorder
GBS-8 =Generic Body-Focused Repetitive Behavior Scale-8
HRT =Habit Reversal Training
IQR =Interquartile Range
MGH-HS =Massachusetts General Hospital Hairpulling Symptom Severity Scale
OCD =Obsessive-Compulsive Disorder
QLESQ-SF =Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form
RBFBS =Repetitive Body Focused Behavior Scale
RBFBS-p=Repetitive Body Focused Behavior Scale-Parent Report
RBFBS-SR =Repetitive Body Focused Behavior Scale-Self Report
SD =Standard Deviation
SNRI =Serotonin-Norepinephrine Reuptake Inhibitor
SSRI =Selective Serotonin Reuptake Inhibitor
TCA =Tricyclic Antidepressant
WHODAS 2.0 =World Health Organization Disability Assessment Schedule 2.0

References:

1. Grant JE. *Trichotillomania, Skin Picking, and Other Body-Focused Repetitive Behaviors*. American Psychiatric Pub; 2012.

2. Houghton DC, Alexander JR, Bauer CC, Woods DW. Body-focused repetitive behaviors: More prevalent than once thought? *Psychiatry Res*. 2018;270:389-393.

3. Grant JE, Chamberlain SR. The role of compulsivity in body-focused repetitive behaviors. *J Psychiatr Res*. 2022;151:365-367.

4. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM-5)*. American Psychiatric Publishing; 2021.

5. Stein DJ, Christenson GA, Hollander E. *Trichotillomania*. American Psychiatric Pub; 1999.

6. Chamberlain GJD Sr. Prevalence, gender correlates, and co-morbidity of trichotillomania. *Psychiatry Research*. 2020;288:112948.

7. Christenson GA, Pyle RL, Mitchell JE. Estimated lifetime prevalence of trichotillomania in college students. *J Clin Psychiatry*. 1991;52(10):415-417.

8. Thomson HA, Farhat LC, Olfson E, Levine JLS, Bloch MH. Prevalence and gender distribution of trichotillomania: A systematic review and meta-analysis. *J Psychiatr Res*. 2022;153:73-81.

9. Bohn M, Thomsen PH, Nissen JB. [Trichotillomania]. *Ugeskr Laeger*. 2022;184(19). https://www.ncbi.nlm.nih.gov/pubmed/35593367

10. Grzesiak M, Reich A, Szepietowski JC, Hadryś T, Pacan P. Trichotillomania Among Young Adults: Prevalence and Comorbidity. *Acta Derm Venereol*. 2017;97(4):509-512.

11. Odlaug BL, Grant JE. Impulse-Control Disorders in a College Sample: Results From the Self-Administered Minnesota Impulse Disorders Interview (MIDI). The Primary Care Companion. doi:10.4088/PCC.09m00842whi

12. Mansueto CS, Thomas AM, Brice AL. Hair pulling and its affective correlates in an African-American university sample. *J Anxiety Disord*. 2007;21(4):590-599.

13. Szepietowski JC, Salomon J, Pacan P, Hrehorów E, Zalewska A. Frequency and treatment of trichotillomania in Poland. *Acta Derm Venereol*. 2009;89(3):267-270.

14. Cohen LJ, Stein DJ, Simeon D, et al. Clinical profile, comorbidity, and treatment history in 123 hair pullers: a survey study. *J Clin Psychiatry*. 1995;56(7):319-326.

15. Lochner C, Keuthen NJ, Curley EE, et al. Comorbidity in trichotillomania (hair-pulling disorder): A cluster analytical approach. *Brain Behav*. 2019;9(12):e01456.

16. Woods DW, Flessner CA, Franklin ME, et al. The Trichotillomania Impact Project (TIP): exploring phenomenology, functional impairment, and treatment utilization. *J Clin Psychiatry*. 2006;67(12):1877-1888.

17. Keuthen NJ, Koran LM, Aboujaoude E, Large MD, Serpe RT. The prevalence of pathologic skin picking in US adults. *Compr Psychiatry*. 2010;51(2):183-186.

18. Hayes, SL, Storch, EA, Berlanga, L. Skin picking behaviors: An examination of the prevalence and severity in a community sample. *Journal of Anxiety Disorders*. 2009;23(3):314-319.

19. Grant JE, Odlaug BL, Chamberlain SR, Keuthen NJ, Lochner C, Stein DJ. Skin picking disorder. *Am J Psychiatry*. 2012;169(11):1143-1149.

20. Ricketts EJ, Snorrason Í, Kircanski K, et al. A latent profile analysis of age of onset in pathological skin picking. *Compr Psychiatry*. 2018;87:46-52.

21. Leppink EW, Lust K, Grant JE. Depression in university students: associations with impulse control disorders. *Int J Psychiatry Clin Pract*. 2016;20(3):146-150.

22. Grant JE, Chamberlain SR. Clinical correlates of symptom severity in skin picking disorder. *Compr Psychiatry*. 2017;78:25-30.

23. Flessner CA, Woods DW. Phenomenological characteristics, social problems, and the economic impact associated with chronic skin picking. *Behav Modif*. 2006;30(6):944-963.

24. Tucker BTP, Woods DW, Flessner CA, Franklin SA, Franklin ME. The Skin Picking Impact Project: phenomenology, interference, and treatment utilization of pathological skin picking in a population-based sample. *J Anxiety Disord*. 2011;25(1):88-95.

25. Azrin NH, Nunn RG. Habit-reversal: a method of eliminating nervous habits and tics. *Behav Res Ther*. 1973;11(4):619-628.

26. Bloch MH, Landeros-Weisenberger A, Dombrowski P, et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. *Biol Psychiatry*. 2007;62(8):839-846.

27. Farhat LC, Olfson E, Nasir M, et al. Pharmacological and behavioral treatment for trichotillomania: An updated systematic review with meta-analysis. *Depress Anxiety*. 2020;37(8):715-727.

28. Henkel ED, Jaquez SD, Diaz LZ. Pediatric trichotillomania: Review of management. *Pediatr Dermatol*. 2019;36(6):803-807.

29. Cisoń H, Kuś A, Popowicz E, Szyca M, Reich A. Trichotillomania and Trichophagia: Modern Diagnostic and Therapeutic Methods. *Dermatol Ther (Heidelb)*. 2018;8(3):389-398.

30. Everett GJ, Jafferany M, Skurya J. Recent advances in the treatment of trichotillomania (hair-pulling disorder). *Dermatol Ther*. 2020;33(6):e13818.

31. Azrin NH, Nunn RG. Habit-reversal: a method of eliminating nervous habits and tics. *Behav Res Ther*. 1973;11(4):619-628.

32. McGuire JF, Ung D, Selles RR, et al. Treating trichotillomania: a meta-analysis of treatment effects and moderators for behavior therapy and serotonin reuptake inhibitors. *J Psychiatr Res*. 2014;58:76-83.

33. Woods DW, Wetterneck CT, Flessner CA. A controlled evaluation of acceptance and commitment therapy plus habit reversal for trichotillomania. *Behav Res Ther*. 2006;44(5):639-656.

34. Keuthen NJ, Rothbaum BO, Fama J, et al. DBT-enhanced cognitive-behavioral treatment for trichotillomania: A randomized controlled trial. *J Behav Addict*. 2012;1(3):106-114.

35. Franklin ME, Edson AL, Ledley DA, Cahill SP. Behavior therapy for pediatric trichotillomania: a randomized controlled trial. *J Am Acad Child Adolesc Psychiatry*. 2011;50(8):763-771.

36. Rahman O, McGuire J, Storch EA, Lewin AB. Preliminary Randomized Controlled Trial of Habit Reversal Training for Treatment of Hair Pulling in Youth. *J Child Adolesc Psychopharmacol*. 2017;27(2):132-139.

37. Schumer MC, Bartley CA, Bloch MH. Systematic Review of Pharmacological and Behavioral Treatments for Skin Picking Disorder. *J Clin Psychopharmacol*. 2016;36(2):147-152.

38. Selles RR, McGuire JF, Small BJ, Storch EA. A systematic review and meta-analysis of psychiatric treatments for excoriation (skin-picking) disorder. *Gen Hosp Psychiatry*. 2016;41:29-37.

39. Falkenstein MJ, Rogers K, Malloy EJ, Haaga DAF. Predictors of Relapse Following Treatment of Trichotillomania. *J Obsessive Compuls Relat Disord*. 2014;3(4):345-353.

40. Marcks BA, Wetterneck CT, Woods DW. Investigating healthcare providers' knowledge of trichotillomania and its treatment. *Cogn Behav Ther*. 2006;35(1):19-27.

41. Capel LK, Petersen JM, Woods DW, Marcks BA, Twohig MP. Mental health providers' knowledge of trichotillomania and skin picking disorder, and their treatment. *Cognit Ther Res*. 2024;48(1):30-38.

42. Sampaio DG, Grant JE. Body-focused repetitive behaviors and the dermatology patient. *Clin Dermatol*. 2018;36(6):723-727.

43. Lee EB, Haeger JA, Levin ME, Ong CW, Twohig MP. Telepsychotherapy for trichotillomania: A randomized controlled trial of ACT enhanced behavior therapy. *J Obsessive Compuls Relat Disord*. 2018;18:106-115.

44. Twohig MP, Petersen JM, Fruge J, et al. A pilot randomized controlled trial of online-delivered ACT-enhanced behavior therapy for trichotillomania in adolescents. *Cogn Behav Pract*. 2021;28(4):653-668.

45. Capel LK, Petersen JM, Becker MR, Levin ME, Twohig MP. The efficacy and feasibility of a fully automated, web-based acceptance-enhanced behavioral treatment for trichotillomania in adults: A randomized waitlist-controlled trial. *J Obsessive Compuls Relat Disord*. 2023;37(100800):100800.

46. Wiese AD, Omar, Y, Swann, AC, Goodman, WK, Storch EA. Habit reversal training for excoriation disorder: Differential outcomes of telehealth versus in-person treatments. *Psychiatry Research Case Reports*. 2023;2(1):100099.

47. Tolin DF, Gilliam C, Wootton BM, et al. Psychometric Properties of a Structured Diagnostic Interview for DSM-5 Anxiety, Mood, and Obsessive-Compulsive and Related Disorders. *Assessment*. 2018;25(1):3-13.

48. Crosby JM, Twohig MP. Habit Reversal. In: *Encyclopedia of Child Behavior and Development*. Springer US; 2011:719-721.

49. Woods DW, Piacentini J, Chang S, et al. *Managing Tourette Syndrome: A Behaviorial Intervention, Adult Workbook. Treatments That Work*. Oxford University Press; 2008.

50. Mansueto CS, Golomb RG, Thomas AM, Stemberger RMT. A comprehensive model for behavioral

treatment of trichotillomania. *Cogn Behav Pract*. 1999;6(1):23-43.

51. Selles RR, La Buissonnière Ariza V, McBride NM, Dammann J, Whiteside S, Storch EA. Initial psychometrics, outcomes, and correlates of the Repetitive Body Focused Behavior Scale: Examination in a sample of youth with anxiety and/or obsessive-compulsive disorder. *Compr Psychiatry*. 2018;81:10-17.

52. Snorrason I, Ricketts EJ, Flessner CA, Franklin ME, Stein DJ, Woods DW. Skin picking disorder is associated with other body-focused repetitive behaviors: findings from an internet study. *Ann Clin Psychiatry*. 2012;24(4):292-299.

53. Keuthen NJ, O'Sullivan RL, Ricciardi JN, et al. The Massachusetts General Hospital (MGH) Hairpulling Scale: 1. development and factor analyses. *Psychother Psychosom*. 1995;64(3-4):141-145.

54. Moritz S, Gallinat C, Weidinger S, et al. The Generic BFRB Scale-8 (GBS-8): a transdiagnostic scale to measure the severity of body-focused repetitive behaviours. *Behav Cogn Psychother*. 2022;50(6):620-628.

55. Henry JD, Crawford JR. The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample. *Br J Clin Psychol*. 2005;44(Pt 2):227-239.

56. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. *Psychopharmacol Bull*. 1993;29(2):321-326.

57. Ustün TB, Chatterji S, Kostanjsek N, et al. Developing the World Health Organization Disability Assessment Schedule 2.0. *Bull World Health Organ*. 2010;88(11):815-823.

58. Mataix-Cols D, Fernández de la Cruz L, Nordsletten AE, Lenhard F, Isomura K, Simpson HB. Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder. *World Psychiatry*. 2016;15(1):80-81.

59. Farhat LC, Olfson E, Levine JLS, et al. Measuring Treatment Response in Pediatric Trichotillomania: A Meta-Analysis of Clinical Trials. *J Child Adolesc Psychopharmacol*. 2020;30(5):306-315.

60. Houghton DC, Capriotti MR, De Nadai AS, et al. Defining treatment response in trichotillomania: a signal detection analysis. *J Anxiety Disord*. 2015;36:44-51.

61. Farhat LC, Olfson E, Li F, Telang S, Bloch MH. Identifying standardized definitions of treatment response in trichotillomania: A meta-analysis. *Prog Neuropsychopharmacol Biol Psychiatry*. 2019;89:446-455.

62. Grant JE, Chamberlain SR. Characteristics of 262 adults with skin picking disorder. *Compr Psychiatry*. 2022;117(152338):152338.

63. Kwon C, Sutaria N, Khanna R, et al. Epidemiology and comorbidities of excoriation disorder: A retrospective case-control study. *J Clin Med*. 2020;9(9):2703.

64. Keuthen NJ, Rothbaum BO, Falkenstein MJ, et al. DBT-enhanced habit reversal treatment for trichotillomania: 3-and 6-month follow-up results. *Depress Anxiety*. 2011;28(4):310-313.

65. Shareh H. A preliminary investigation of metacognitive therapy and habit reversal as a treatment for trichotillomania. *Behav Cogn Psychother*. 2017;46(1):1-20.

66. Lee MT, Mpavaenda DN, Fineberg NA. Habit Reversal Therapy in Obsessive Compulsive Related Disorders: A systematic review of the evidence and CONSORT evaluation of Randomized Controlled Trials. *Front Behav Neurosci*. 2019;13:79.

67. Mouton-Odum S, Keuthen NJ, Wagener PD, Stanley MA. StopPulling.Com: An interactive, self-help program for trichotillomania. *Cogn Behav Pract*. 2006;13(3):215-226.

68. Flessner CA, Mouton-Odum S, Stocker AJ, Keuthen NJ. StopPicking.com: Internet-based treatment for self-injurious skin picking. *Dermatol Online J*. 2007;13(4):3.

69. Gallinat C, Moessner M, Haenssle HA, Winkler JK, Backenstrass M, Bauer S. An internet-based self-help intervention for skin picking (SaveMySkin): Pilot randomized controlled trial. *J Med Internet Res*. 2019;21(9):e15011.

70. Arabatzoudis T, Rehm IC, Nedeljkovic M. A needs analysis for the development of an internet-delivered cognitive-behavioural treatment (iCBT) program for trichotillomania. *J Obsessive Compuls Relat Disord*. 2021;31(100689):100689.

71. Baumeister A, Schmotz S, Weidinger S, Moritz S. Is self-help dangerous? Examination of adverse effects of a psychological internet-based self-help intervention for body-focused repetitive behavior (free from BFRB). *Behav Ther*. 2024;55(1):136-149.

72. Dar R, Schonbach M, Wenzler S. Efficacy of internet-based, therapist-assisted treatment programs for hair pulling and skin picking: Preliminary results. *Cognit Ther Res*. 2024;48(1):66-74.

Table 1. Demographics and psychometrics

Characteristic	Trichotillomania		Excoriation	
	n (%)	Mean (SD)	*n* (%)	Mean (SD
Age	540	26.54 (11.08)	528[1] (100.00)	27.9 (11
Gender				
Female	411 (76.1)		401 (75.9)	
Male	68 (12.6)		66 (12.5)	
Not Reported or Prefer not to say	61 (11.3)		61 (11.6)	
Other[1]	3 (0.6)		26 (4.9)	
Race and Ethnicity				
White	262 (48.5)		308 (58.3)	
Not Recorded	122 (22.6)		98 (18.6)	
More than one race	38 (7.0)		36 (6.8)	
Hispanic or Latino	34 (6.3)		24 (4.5)	
Black or African American	32 (5.9)		18 (3.4)	
Asian, Asian American, or Pacific Islander	26 (4.8)		21 (4.0)	
Undisclosed	11 (2.0)		14 (2.7)	
Other	14 (2.6)		8 (1.5)	
American Indian or Alaska Native	1 (0.2)		1 (0.2)	
Pay				
Insurance pay	441 (81.7)		446 (84.5)	
Cash pay	99 (18.3)		82 (15.5)	
RBFBS[a] (baseline)	543 (100.0)	7.84 (2.29)	528 (100.0)	7.9 (2
WHODAS[b] (baseline)	382 (70.3)	7.98 (6.02)	417 (79.0)	9.4 (7
QLESQ[c] (baseline)	390 (71.8)	63.19 (13.29)	421 (79.7)	60.5 (15
DASS[d] (baseline)				
Anxiety	488 (89.9)	7.19 (7.05)	491 (93.0)	7.5 (7
Depression	488 (89.9)	9.47 (8.17)	491 (93.0)	10.0 (8
Stress	488 (89.9)	14.41 (8.27)	491 (93.0)	14.7 (8
Psychiatric Medication[2]	111 (20.6)		132 (25.0)	

	Trichotillomania		Excoriation	
SSRI[e]	74 (13.7)		87 (16.5)	
ADHD medication[f]	30 (5.6)		32 (6.1)	
Other antidepressant[g]	24 (4.4)		20 (3.8)	
Anti-anxiety/sedative-hypnotic[h]	24 (4.4)		17 (3.2)	
Antipsychotic[i]	7 (1.3)		16 (3.0)	
SNRI[j]	8 (1.5)		13 (2.5)	
Anticonvulsant/mood stabilizer[k]	6 (1.1)		11 (2.1)	
TCA[l]	3 (0.6)		5 (0.9)	
Ketamine	0 (0.0)		2 (0.4)	
Comorbid Diagnoses[3]	**Trichotillomania**		**Excoriation**	
OCD-related Disorder[m]	159 (29.3)		117 (22.2)	
Anxiety Disorders[n]	202 (37.2)		215 (40.7)	
Mood Disorders[o]	116 (21.4)		165 (31.2)	
Trauma and Stress-Related Disorders[p]	23 (4.2)		26 (4.9)	
ADHD	15 (2.8)		16 (3.0)	
Eating Disorders[q]	7 (1.3)		7 (1.3)	
Substance Use Disorders[r]	6 (1.1)		11 (2.1)	
Tic or Tourette's Disorder	7 (1.3)		21 (4.0)	
Somatic Symptom Disorders	6 (1.1)		6 (1.1)	
Adjustment Disorders	5 (0.9)		4 (0.8)	
Oppositional Defiant Disorder	2 (0.4)		5 (0.9)	
Autism Spectrum Disorder	1 (0.2)		3 (0.6)	
At Least One Comorbidity	337 (62.1)		353 (66.9)	
Single Comorbidity	179 (33.0)		181 (34.3)	
Multiple Comorbidities	158 (29.1)		172 (32.6)	

[1]"Other" category in the trichotillomania sample includes Gender-Queer (0.6%), Gender-Fluid (0.4%), Non-binary (0.2%), and Transgender Male (0.2%) individuals. Excoriation sample includes Non-binary (2.8%), Transgender Male (0.6%), Gender-Queer (0.8%), Transgender (as non-binary) (0.2%), and Other (0.6%) individuals.

[2]Some individuals were on more than one psychiatric medication, or had more than one comorbidity total across categories > 100%

[a]RBFBS = Repetitive Body Focused Behavior Scale
[b]WHODAS = World Health Organization Disability Assessment Schedule
[c]QLESQ = Quality of Life Enjoyment and Satisfaction Questionnaire—Short Form

[d]DASS = Depression Anxiety and Stress Scale—21
[e]SSRI = Selective serotonin reuptake inhibitor
[f]ADHD medications = Includes stimulants (methylphenidate, amphetamine derivatives), non-stimulants (atomoxetine), and alpha-2 adrenergic agonists (clonidine, guanfacine)
[g]Other antidepressants = Includes norepinephrine-dopamine reuptake inhibitors (bupropion), serotonin antagonist and reuptake inhibitors (trazodone), and tetracyclic antidepressants (mirtazapine)
[h]Anti-anxiety/sedative-hypnotics = Includes non-benzodiazepine anti-anxiety agents (hydroxyzine, buspirone), benzodiazepines (clonazepam, lorazepam), and beta blockers (propranolol)
[i]Antipsychotics = Includes both typical and atypical antipsychotics (aripiprazole, quetiapine, risperidone, ziprasidone)
[j]SNRI = Serotonin–norepinephrine reuptake inhibitor
[k]Anticonvulsant/mood stabilizers = Includes anticonvulsants (lamotrigine, gabapentin, oxcarbazepine) and non-anticonvulsant mood stabilizers (lithium)
[l]TCA = Tricyclic antidepressant (e.g., clomipramine)
[m]OCD-related disorders = Includes other OCD, body dysmorphic disorder, hoarding disorder, and trichotillomania/excoriation (except when primary diagnosis)
[n]Anxiety disorders = Includes generalized anxiety, panic disorder, social/specific phobias, agoraphobia
[o]Mood disorders = Includes major depression, dysthymia, bipolar disorders, mixed/manic episodes, physiological mood conditions
[p]Trauma and Stress-Related Disorders = Includes post-traumatic stress disorder (PTSD), acute stress, adjustment reactions
[q]Eating Disorders = Includes binge eating, other specified eating disorder
[r]Substance Use Disorders = Includes alcohol, opioid, and cannabis use disorders

Table 2. RBFBS Scores by Age Group, Condition, and Time Point

Age Group		Trichotillomania			Excoriation		
		Baseline	Week 5-7	Week 14-16	Baseline	Week 5-7	Week 14-16
Children	n(%)	57 (100.00)	57 (100.00)	47 (82.46)	40 (100.00)	40 (100.00)	30 (75.00)
	M (SD)	5.95 (2.49)	4.93 (2.70)	4.11 (2.55)	6.22 (2.01)	5.42 (2.33)	3.33 (2.04)
Adolescents	n(%)	75 (100.00)	75 (100.00)	62 (82.67)	46 (100.00)	46 (100.00)	35 (76.09)
	M (SD)	7.39 (2.32)	6.25 (2.61)	5.21 (2.80)	6.65 (2.24)	5.46 (2.71)	4.54 (2.82)
Adults	n(%)	408 (100.00)	408 (100.00)	311 (76.23)	442 (100.00)	442 (100.00)	344 (77.83)
	M (SD)	8.20 (2.11)	6.36 (2.66)	5.47 (2.70)	8.17 (2.03)	6.52 (2.47)	5.35 (2.52)

Note: M = Mean; RBFBS = Repetitive Body Focused Behavior Scale; SD = Standard Deviation

Age category data was missing for 3 trichotillomania members (0.6% of sample) who otherwise met all inclusion criteria. These participants had baseline scores M=6.67 (SD=2.08), midpoint scores M=6.00 (SD=0.00), and for the 2 who completed the endpoint assessment, M=4.00 (SD=4.24).

Table 3. Clinical assessments by treatment time point

Outcome scale and assessment time point	Trichotillomania			Excoriation		
	Valid, n	Missing[*], n	Mean (SD)	Valid, n	Missing[*], n	Mean (SD)
RBFBS[a]						
Baseline	543	0	7.84 (2.29)	528	0	7.89 (2.14)
Week 5-7	543	0	6.19 (2.68)	528	0	6.34 (2.51)
Week 14-16	422	121	5.27 (2.73)	409	119	5.13 (2.57)
Week 17-28	365	178	4.83 (2.79)	345	183	4.59 (2.31)
Week 29-40	229	314	4.51 (2.59)	205	323	4.40 (2.07)
Week 41-52	122	421	4.23 (2.50)	134	394	4.40 (2.32)
DASS[b] depression						
Baseline	488	55	9.47 (8.17)	491	37	9.99 (8.84)
Week 5-7	508	35	8.42 (8.17)	505	23	8.83 (8.08)
Week 14-16	406	137	7.26 (7.64)	398	130	7.43 (7.28)
DASS anxiety						
Baseline	488	55	7.19 (7.05)	491	37	7.54 (7.22)
Week 5-7	508	35	6.59 (6.97)	505	23	6.74 (6.42)
Week 14-16	406	137	5.65 (6.30)	398	130	5.86 (6.01)
DASS stress						
Baseline	488	55	14.41 (8.27)	491	37	14.66 (8.09)
Week 5-7	508	35	13.35 (8.41)	505	23	13.98 (7.70)
Week 14-16	406	137	11.96 (8.10)	398	130	12.30 (7.53)
QLESQ[c]						
Baseline	390	153	63.19 (13.29)	421	107	60.49 (14.98)
Week 5-7	402	141	65.10 (13.62)	433	95	62.82 (15.08)

Week 14-16	309	234	67.07 (15.04)	341	187	65.14 (14.51)
WHODAS[d]						
Baseline	382	161	7.98 (6.02)	417	111	9.35 (7.32)
Week 5-7	398	145	7.15 (6.09)	427	101	8.77 (7.38)
Week 14-16	305	238	6.03 (6.37)	338	190	7.30 (6.69)

[*]Missing n's reflect patients who discontinued or completed treatment prior to that assessment timepoint. Treatment completion could occur due to meeting treatment goals, premature discontinuation, or switching to treating another condition as primary. Due to the naturalistic study design, we could not reliably differentiate between these reasons for their treatment ending. For weeks 17-52, missing n's represent those who did not participate in optional follow-up assessments after the active treatment phase (weeks 1-16).

[a]RBFBS: Repetitive Body Focused Behavior Scale
[b]DASS: Depression Anxiety and Stress Scale—21
[c]QLESQ: Quality of Life Enjoyment and Satisfaction Questionnaire—Short Form
[d]WHODAS = World Health Organization Disability Assessment Schedule (2.0)

Figure 1. RBFBS Scores by Assessment Period

a)

b)

Note: RBFBS = Repetitive Body Focused Behavior Scale

Changes in a) trichotillomania (top) and b) excoriation (bottom) symptoms as assessed by the RBFBS with treatment. Median and IQRs are indicated in the box-and-whisker plots. *P*<.001 for the effect of assessment period.

Figure 2. Longitudinal RBFBS Scores by Assessment Period

a)

b)

Note: RBFBS = Repetitive Body Focused Behavior Scale

Changes in a) trichotillomania (top) and b) excoriation (bottom) symptoms as assessed by the RBFBS with treatment through 52-week follow-up. Median and IQRs are indicated in the box-and-whisker plots. P<.001 for the effect of assessment period.